Poor
Partially Aligned
Patient Risk:
Low
Summary
Majority of AI-generated claims about turmeric and Eliquis are not supported by the FDA-approved label; only a small subset aligns (bleeding risk with Eliquis and general counseling language).
Category Scores
Accurate Statements
Eliquis already raises bleeding risk.
5.2
Easy, widespread bruising or bleeding that won’t stop.
17
Unsupported Statements
Turmeric (and the active compound curcumin) can have blood-thinning effects in some lab and animal studies.
Not supported by label; label does not describe turmeric/curcumin as a bleeding risk in preclinical studies.
Turmeric supplements have the potential to increase bleeding risk when taken with anticoagulants like Eliquis (apixaban).
Not supported; label discusses bleeding risk with drugs affecting hemostasis (5.2) and general interactions (7.3) but does not mention turmeric/curcumin specifically.
Combining Eliquis with turmeric products may increase the chance of bruising, nosebleeds, or more serious bleeding.
Not supported; no turmeric-specific interaction described in label.
If you’re taking turmeric as a food (small culinary amounts), the risk is generally lower than with high-dose supplements.
Not supported; label does not quantify risk by turmeric dose.
Bleeding risk is more likely to matter with turmeric extracts, curcumin pills, or “turmeric +” combination products that deliver concentrated doses.
Not supported; label does not discuss turmeric extracts vs foods.
Blood in urine.
Not supported; label does not specify hematuria.
Blood in stool.
Not supported; label does not specify hematochezia.
Black/tarry stools.
Not supported; label does not specify this sign.
Vomiting blood.
Not supported; label does not specify hematemesis.
Severe or persistent headaches.
Not supported; label does not list this adverse event specifically.
Dizziness.
Not supported; label does not list dizziness as an adverse event.
Weakness.
Not supported; label does not list this adverse event specifically.
Trouble speaking.
Not supported; label does not list this adverse event specifically.
Unusual or heavy bleeding (for example, menstrual bleeding that’s much heavier than usual).
Not supported; label does not specify menstrual bleeding.
The interaction depends on turmeric form and dose.
Not supported; label does not discuss turmeric form/dose interactions.
The potential problem is far more likely with concentrated supplements than with cooking use.
Not supported; label does not compare supplement vs cooking use for turmeric.
Products with higher curcumin content (or “enhanced” bioavailability formulations) can deliver much larger active doses than typical dietary intake.
Not supported; label does not address curcumin content or bioavailability formulations.
Turmeric is just one example.
Not supported; label does not present turmeric as an example amid other supplements.
Other supplements often discussed with anticoagulants include high-dose omega-3s, ginger, garlic tablets, ginkgo, and others that may increase bleeding risk.
Not supported; label does not enumerate these supplements in relation to turmeric.
The safest approach is to review all supplements with a pharmacist or prescriber when you’re on Eliquis.
Not supported; label emphasizes informing about products that affect bleeding but does not provide this general review recommendation.
Contradictions
Important Omissions
Direct turmeric/curcumin interaction with Eliquis is not described; label provides general bleeding risk with concomitant drugs (5.2) and drug interactions (7.3) but does not mention turmeric specifically.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Most claims are not supported by the label; however, the label's bleed risk guidance with concomitant agents is relevant. Inaccurate turmeric-specific claims could mislead patients.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Partially Aligned
Primary Issue
Many claims are not supported by the FDA label; only general bleeding risk and drug interaction language is applicable.
Suggested Improvement
Limit to label-supported statements; cite 5.2, 7.3, and 17 sections; avoid turmeric-specific interaction assertions; for patient guidance, reference exact Counseling points.